S. 5265 · 119th Congress — USTRx Act
Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U. S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce…
- Congress
- 119
- Bill
- S 5265
- Status
- Introduced
- Introduced
- 2026-08-05
- Latest action date
- 2026-08-05
Record overview
Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U. S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U. S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U. S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.
The recorded stage is committee referral: the named committee or committees consider the parts within their jurisdiction. Referral alone does not mean the measure has passed Congress or become law.
Latest action
Read twice and referred to the Committee on Finance.
Sponsors
- Sen. Sheehy, Tim [R-MT]
Montana · Senate · Republican
Record provenance
Stored record updated: 2026-09-16. This is separate from the action date and does not establish enactment.